Companies Reporting Before The Bell
• AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
Here is a look at the most-searched-for stocks on Benzinga Pro in the month of April.
Protalix BioTherapeutics Inc (NYSE:PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., have announced topline data from the BALANCE Phase…
Protalix BioTherapeutics Inc (AMEX:PLX) shares are surging Monday after the company said its Phase 3 trial for the treatment of Fabry disease met its primary endpoint.
Fabry disease is an inherited disease resulting in progressive accumulation of abnormal deposits of a fatty substance in blood vessel walls throughout a person's body.
Protalix BioTherapeutics (AMEX:PLX) reported its Q4 earnings results on Thursday, March 31, 2022 at 06:50 AM.
Here's what investors need to know about the announcement.
Study achieved key objectives for safety, efficacy and pharmacokinetics
After completion of the study, all patients enrolled in an extension study
Treatment with PRX-102 provided coverage for the entire four‑week period